Visit https://www.peervoice.com/JGH860 to view the entire programme with slides. After completing “David Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma”, participants will be able to: Evaluate current evidence-based treatment options in patients with cholangiocarcinoma (CCA) who have actionable mutations, with a focus on FGFR2 alterations; Identify key clinical challenges encountered in the targeted treatment of FGFR2-fusion–positive CCA; and Formulate personalised management plans for patients with CCA who are treated with FGFR inhibitors.